Navigation Links
Uranium exposure linked to increased lupus rate
Date:11/13/2012

CINCINNATIPeople living near a former uranium ore processing facility in Ohio are experiencing a higher than average rate of lupus, according a new study conducted by scientists at the University of Cincinnati and Cincinnati Children's Hospital Medical Center.

Lupus is a chronic inflammatory disease that can affect the skin, joints, kidneys, lungs, nervous system and other organs of the body. The underlying causes of lupus are unknown, but it is usually more common in women of child-bearing age.

For this new study, a collaborative team of UC and Cincinnati Children's researchers wanted to compare lupus rates between people who were exposed to uranium and those who were not in an effort to explain the high number of lupus cases reported in a Cincinnati community.

Extensive review of medical records and serum antibody analysis to verify the cases, concluded that people who were exposed to higher levels of uranium, based on their living proximity to a former uranium ore processing plant, had lupus rates four times higher than the average population.

"Former studies have suggested that people with lupus may be more sensitive to radiation and that both genetics and environmental exposures play a role in disease development. Our study shows a strong correlation between uranium exposure, a radioactive substance, and an increased lupus rate that merits further investigation," says Pai-Yue Lu, MD, a pediatric rheumatology fellow at Cincinnati Children's and lead researcher for the study.

"With more research in this area, we may gain additional insight on the types of environmental factors that contribute to lupus development and the mechanisms by which they work," Lu adds. "There could be other effects of uranium and related exposures that could contribute to or help explain our findings."

Lu is presenting this finding and its potential implication at the American College of Rheumatology Annual Scientific Meeting Monday, Nov. 12, in Washington, D.C. She completed the project as part of her master's degree in clinical and translational science training at UC.

The Cincinnati-based team's research is based on nearly two decades of data collected through the Fernald Medical Monitoring Program, the United States' first and largest legally mandated comprehensive medical monitoring program. The program was established in 1990 after a federal investigation revealed that National Lead of Ohio's Feed Materials Production Center in the Hamilton County, Ohio, community of Fernald, was emitting dangerous levels of uranium dust and gases into the surrounding communities.

"The availability of this cohort and carefully collected data and biospecimens provides a great setting to ask research questions," says Susan Pinney, PhD, UC professor of environmental health and principal investigator of the Fernald study.

Almost 10,000 community residents enrolled in the Fernald Medical Monitoring Program. Community residents were classified into several exposure groups: high exposure, moderate exposure, low exposure and no exposure. (Uranium plant workers were not part of this study.)

"Typical U.S. incidence rates for lupus are 1.8 to 7.6 cases per 100,000. Among the 25 confirmed lupus cases we identified through the Fernald community cohort, 12 were in the high exposure group, eight with moderate exposure and five in the low exposure group," says Lu.


'/>"/>
Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
Source:Eurekalert

Related biology news :

1. Combined pesticide exposure affects bumblebee colony success
2. New model could help fill data gap in predicting historical air pollution exposure
3. Chemical exposure in the womb from household items may contribute to obesity
4. Tracking the effects of prenatal alcohol exposure through to 9 years of age
5. Socioeconomics may affect toddlers exposure to flame retardants
6. NOAA discovers way to detect low-level exposure to seafood toxin in marine animals
7. Effect of chronic exposure to chemicals used as weapons, pesticides under study
8. Prenatal exposure to air pollution linked to childhood obesity
9. Obese patients face higher radiation exposure from CT scans -- but new technology can help
10. Lower dosage CT-guided lung biopsy protocol maintains quality, minimizes exposure
11. Exposure to antibiotics linked to severity of allergic asthma: UBC research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology: